规格 | 价格 | 库存 | 数量 |
---|---|---|---|
100mg |
|
||
500mg |
|
||
1g |
|
||
5g |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
LPS 激活的 BV2 小胶质细胞可以改变其免疫学特征,并通过亚甲蓝 (Basic Blue 9)(4.5 μM;BV2 小胶质细胞)降低其 CD14、IL-1β、TNF-α 和 CCL2 mRNA 水平 [3]。
|
---|---|
体内研究 (In Vivo) |
每 25 分钟一次以 50 和 100 mg/kg 的剂量腹膜内给予雄性 NMRI 小鼠一次亚甲蓝(Basic Blue 9)可减少前脉冲抑制的不足[1]。 ?在表达全长促聚集人类 Tau 能力的小鼠中,Basic Blue 9(20 和 40 mg/kg;口服;每天一次,持续 6 个月;CaMKIIα-tTA 反式激活小鼠)保留了认知能力[2]。 ?在经 TBI 治疗的雄性 BALB/c 小鼠中,Basic Blue 9(2 mg/kg;静脉注射;1 天一次)可减少最初的抑郁样行为以及 TBI 引起的水肿和神经炎症 [3]。 ?通过每天一次以 2 mg/kg 的剂量静脉注射亚甲蓝(Basic Blue 9),TBI 治疗的雄性 BALB/c 小鼠中炎症因子的百分比降低[3]。
|
动物实验 |
Animal/Disease Models: Male NMRI mice [1]
Doses: 50 and 100 mg/kg Route of Administration: intraperitoneal (ip) injection; once for 25 minutes Experimental Results: diminished prepulse inhibition and diminished phencyclidine (PCP)-induced locomotor activity Increase. Animal/Disease Models: CaMKIIα-tTA transactivated mice [2] Doses: 20 and 40 mg/kg Route of Administration: Oral; one time/day for 6 months Experimental Results: Inhibition of Tau aggregation in CaMKIIα-tTA transactivated mice . Animal/Disease Models: TBI-treated male balb/c (Bagg ALBino) mouse [3] Doses: 2 mg/kg Route of Administration: intravenous (iv) (iv)injection; once for 1 day Experimental Results: CD14, IL-1β, TNF-α and CCL2 mRNA levels were diminished. Animal/Disease Models: TBI-treated male balb/c (Bagg ALBino) mouse [3] Doses: 2 mg/kg Route of Administration: intravenous (iv) (iv)injection; once for 1 day Experimental Results: The percentage of bone marrow (CD11b+/GR1+) cells in microglia diminished , IL-1β was diminished and IL-10 expression was enhanced. |
参考文献 |
[1]. Klamer D, et, al. Phencyclidine-induced behaviour in mice prevented by methylene blue. Basic Clin Pharmacol Toxicol. 2004 Feb;94(2):65-72.
[2]. Hochgräfe K, et, al. Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. Acta Neuropathol Commun. 2015 May 10;3:25. [3]. Fenn AM, et, al. Methylene blue attenuates traumatic brain injury-associated neuroinflammation and acute depressive-like behavior in mice. J Neurotrauma. 2015 Jan 15;32(2):127-38. |
分子式 |
C16H18CLN3S
|
---|---|
分子量 |
319.85222
|
CAS号 |
61-73-4
|
相关CAS号 |
Methylene blue trihydrate;7220-79-3;Methylene blue hydrate;122965-43-9
|
SMILES |
CN(C)C1=CC=C2C(SC(C(C=C/3)=N2)=CC3=[N+](C)/C)=C1.[Cl-]
|
别名 |
CI52015.; Methylene blue
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
H2O : ~50 mg/mL (~156.32 mM)
|
---|---|
溶解度 (体内) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 3.1265 mL | 15.6323 mL | 31.2647 mL | |
5 mM | 0.6253 mL | 3.1265 mL | 6.2529 mL | |
10 mM | 0.3126 mL | 1.5632 mL | 3.1265 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。